Coherus Oncology (CHRS) EBT (2013 - 2026)

Coherus Oncology has disclosed EBT across 14 years of filings, most recently posting -$33.3 million for Q2 2026.

• In Q2 2026, EBT rose 25.67% year-over-year to -$33.3 million; the TTM figure through Jun 2026 stood at -$161.1 million (up 13.34% YoY), while the FY2025 annual figure was -$183.1 million, up 14.98% from the prior year.
• EBT came in at -$33.3 million for Q2 2026 at Coherus Oncology, up from -$36.9 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$33.3 million in Q2 2026 to a low of -$96.1 million in Q1 2022.
• Average EBT over 5 years is -$55.6 million, with a median of -$47.5 million recorded in 2024.
• Year-over-year, EBT tumbled 124.9% in 2022 and surged 53.81% in 2023.
• Over 5 years, EBT stood at -$58.9 million in 2022, then slumped by 35.3% to -$79.7 million in 2023, then soared by 42.13% to -$46.1 million in 2024, then dropped by 0.55% to -$46.3 million in 2025, then rose by 28.05% to -$33.3 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$33.3 million in Q2 2026, -$36.9 million in Q1 2026, and -$46.3 million in Q4 2025.